title: Changes in CA125 release and surface expression caused by drugs in uterine cervix adenocarcinoma cells.
abstract: The effect of drugs on the release of CA125 antigen and the binding of anti-CA125 monoclonal antibody (MoAb) to malignant cells was evaluated in vitro. TMCC-1, uterine cervical adenocarcinoma cells, were exposed to dexamethasone (DEX), sodium n-butyrate (NaB), dibutyryl cyclic AMP (dbcAMP), retinoic acid (RA), calcitriol (VD3), and interferon-gamma (IFN-gamma). NaB, RA and VD3 increased CA125 release per cell and 125I-labeled anti-CA125 MoAb binding to the cells. DEX also increased the 125I-labeled anti-CA125 MoAb binding to the cells, and CA125 antigen release per cell was also slightly increased. IFN-gamma suppressed both CA125 release and 125I-labeled MoAb binding. A combination of DEX, VD3 and RA and increased the binding of MoAb to TMCC-1 cells, but the amount of bound MoAb was not significantly different from that obtained by single drug treatment. DbcAMP had no significant effect on enhancing MoAb binding. Drugs can increase the binding of anti-CA125 MoAb to malignant cells and they may be applied to increase the tumor uptake of radiolabeled MoAbs in vivo.
authors.affiliation: Department of Nuclear Medicine, Kyoto University School of Medicine, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Nakai
authors.forename: H
authors.initials: H
authors.lastname: Sakahara
authors.forename: K
authors.initials: K
authors.lastname: Endo
authors.forename: M
authors.initials: M
authors.lastname: Shirato
authors.forename: H
authors.initials: H
authors.lastname: Kobayashi
authors.forename: M
authors.initials: M
authors.lastname: Hosono
authors.forename: T
authors.initials: T
authors.lastname: Saga
authors.forename: M
authors.initials: M
authors.lastname: Sakamoto
authors.forename: J
authors.initials: J
authors.lastname: Konishi
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology*; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000096:biosynthesis*; D003994:Bucladesine / Q000494:pharmacology*; D002087:Butyrates / Q000494:pharmacology*; D020148:Butyric Acid; D002117:Calcitriol / Q000494:pharmacology*; D003907:Dexamethasone / Q000494:pharmacology*; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D007371:Interferon-gamma / Q000494:pharmacology*; D014212:Tretinoin / Q000494:pharmacology*; D002583:Uterine Cervical Neoplasms / Q000473:pathology*
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate; D002087:Butyrates; D020148:Butyric Acid; D014212:Tretinoin; D003994:Bucladesine; D003907:Dexamethasone; D007371:Interferon-gamma; D002117:Calcitriol